An estimated 250,000 intravascular device-related bloodstream infections occur in the United States annually, often acquired as a result of hemodialysis treatment.
We believe most bloodstream infections are avoidable. Our mission is to reduce incidence of catheter-related bloodstream infections among patients using infusion catheters, in the United States and around the globe.
Nitric Oxide is a powerful molecule that kills bacteria and disperses biofilm. Applied as an antimicrobial agent for infusion catheters, it brings to the healthcare community the potent tool it needs to fight bloodstream infections.
The NitriCap team is seasoned with experience in entrepreneurship, medicine, research, and both business development strategy and execution. The team possesses the balanced skillsets needed to transform proven research technology to commercial release via 510(k) clearance pathway.
Copyright © 2020 NitriCap Medical Inc. - All Rights Reserved.